title: Comparison of sucralfate and ranitidine in the treatment of duodenal ulcers.
abstract: Ninety patients with endoscopically proven duodenal ulcers, enrolled in this prospective, single-blind study, were randomized to sucralfate, 1 g q.i.d., 0.5 hour before meals on an empty stomach or at bedtime, or ranitidine, 150 mg b.i.d., for 4-8 weeks (phase I). Patients who healed during the treatment period were invited to participate in a maintenance therapy follow-up covering 1 year (phase II), during which they were treated with sucralfate, 1 g b.i.d. (before breakfast and at bedtime) or 150 mg of ranitidine at bedtime. After 4 weeks of treatment, healing rates were 30/40 (75.0%) with sucralfate and 36/42 (85.7%) with ranitidine, and healing rates were 39/40 (97.6%) and 40/42 (95.2%) respectively, after 8 weeks of treatment. At the end of the 6th and 12th months of phase II, respectively, relapse rates were 3/33 (9.4%) and 10/32 (31.3%) in the sucralfate group and 5/33 (15.2%) and 10/29 (34.5%) in the ranitidine group. Differences between sucralfate- and ranitidine-treated groups were not significant. Both treatments were well tolerated. We conclude that sucralfate is as effective and safe as ranitidine in the short-term treatment and prevention of relapse in patients with ulcer disease.
authors.affiliation: Gastroenterology Service, Hospital Clinico San Carlos, Madrid, Spain.
authors.forename: J
authors.initials: J
authors.lastname: Garcia-Paredes
authors.forename: M
authors.initials: M
authors.lastname: Diaz Rubio
authors.forename: F
authors.initials: F
authors.lastname: Llenas
authors.forename: C
authors.initials: C
authors.lastname: Taxonera
authors.forename: L
authors.initials: L
authors.lastname: Pardo
mesh_terms: D000284:Administration, Oral; D000328:Adult; D003258:Consumer Behavior; D004381:Duodenal Ulcer / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011899:Ranitidine / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D012008:Recurrence; D012907:Smoking / Q000009:adverse effects / Q000453:epidemiology; D013392:Sucralfate / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D014945:Wound Healing / Q000187:drug effects
chemical_list: D013392:Sucralfate; D011899:Ranitidine